Kang-Ai Injection Inhibits Gastric Cancer Cells Proliferation through IL-6/STAT3 Pathway

Chun-lei ZHENG; Ke-zuo HOU; An-qi WANG; Wan-xia FANG; Shi-tong YU; Jin-e LIANG; Hai-yan QI; Xiu-juan QU; Yun-peng LIU; Xiao-fang CHE

doi:10.1007/s11655-020-3265-6

Your Location：

Home >

Browse articles >

Kang-Ai Injection Inhibits Gastric Cancer Cells Proliferation through IL-6/STAT3 Pathway

Original Article | Updated：2022-06-27

- Kang-Ai Injection Inhibits Gastric Cancer Cells Proliferation through IL-6/STAT3 Pathway
- Chinese Journal of Integrative Medicine Vol. 28, Issue 6, Pages: 524-530(2022)
- Affiliations：
  
  1.Department of Medical Oncology, the First Hospital of China Medical University, Shenyang (110001), China
  2.Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University,Shenyang (110001), China
  3.Liaoning Province Clinical Research Center for Cancer, Shenyang (110001), China
- Author bio：
  
  Associate Prof. CHE Xiao-fang, E-mail:xfche@cmu.edu.cn
- Funds：
- DOI：10.1007/s11655-020-3265-6
  CLC：
- Published：01 June 2022，
  
  Published Online：09 July 2020，
  
  Accepted：26 December 2019
Scan for full text
Chun-lei ZHENG, Ke-zuo HOU, An-qi WANG, et al. Kang-Ai Injection Inhibits Gastric Cancer Cells Proliferation through IL-6/STAT3 Pathway. [J]. Chinese Journal of Integrative Medicine 28(6):524-530(2022)
DOI：

Chun-lei ZHENG, Ke-zuo HOU, An-qi WANG, et al. Kang-Ai Injection Inhibits Gastric Cancer Cells Proliferation through IL-6/STAT3 Pathway. [J]. Chinese Journal of Integrative Medicine 28(6):524-530(2022) DOI： 10.1007/s11655-020-3265-6.

摘要

目的:

探讨中药康艾注射液 (KAI) 抑制胃癌细胞增殖的机制.

方法:

利用KAI (0、0.3%、1%、3%和10%)分别处理MGC803和BGC823胃癌细胞株24、48和72小时. MTT法检测细胞增殖活性; 流式细胞仪检测细胞凋亡和细胞周期; 采用实时定量聚合酶链反应(qRT-PCR)和酶联免疫吸附试验(ELISA)分别检测白细胞介素(IL)-6 mRNA及蛋白表达水平; Western blot检测细胞周期相关蛋白cyclinA/E/B1/D1、p21、RB及AKT、ERK、STAT1、STAT3的蛋白表达水平.

结果:

KAI以剂量和时间依赖方式抑制胃癌MGC803和BGC823细胞增殖. KAI处理胃癌细胞48小时后

G1期细胞比例增加

cyclinD1和磷酸化RB(p-RB) 表达水平降低

p21表达水平升高 (均

0.01) ; p-STAT3水平降低、IL-6 mRNA及蛋白表达水平受到抑制 (均

0.01) . 10 ng/mL IL-6可明显减弱3%和10% KAI对胃癌细胞增殖的抑制作用

部分恢复KAI抑制的STAT3磷酸化和细胞周期蛋白D1表达 (均

0.01) .

结论:

KAI通过抑制IL-6/STAT3信号通路诱导G1期阻滞而抑制胃癌细胞增殖.

Abstract

Objective:

To explore the mechanisms underlying the proliferative inhibition of Chinese herbal medicine Kang-Ai injection (KAI) in gastric cancer cells.

Methods:

Gastric cancer cell lines MGC803 and BGC823 were treated by 0

0.3%

3% and 10% KAI for 24

48 and 72 h

respectively. The cell proliferation was evaluated by 3-(4

5-dimethyl-2-thiazolyl)-2

5-diphenyl-2-H-tetrazolium bromide (MTT) assay. The apoptosis and cell cycle were evaluated by flow cytometry. Interleukin (IL)-6 mRNA and protein expression levels were detected by quantitative real-time polymerase chain reaction (qRT-PCR) and enzyme-linked immune sorbent assay (ELISA)

respectively. The protein expression levels of cyclin A

cyclin E

cyclin B1

cyclin D1

p21

retinoblastoma (RB)

protein kinase B (AKT)

extracellular regulated protein kinases (ERK)

signal transducer and activator of transcription (STAT) 1 and STAT3 were detected by Western blot.

Results:

KAI inhibited the proliferation of MGC803 and BGC823 gastric cancer cells in dose- and time-dependent manner. After treated with KAI for 48 h

the proportion of G1 phase was increased

expression level of cyclin D1 and phosphorylation-RB were down-regulated

whereas the expression of p21 was up-regulated (all

0.01). Furthermore

48-h treatment with KAI decreased the phosphorylation level of STAT3

inhibited the mRNA and protein expressions of IL-6 (all

0.01). IL-6 at dose of 10 ng/mL significantly attenuated the proliferative effect of both 3% and 10% KAI

and recovered KAI-inhibited STAT3 phosphorylation and cyclin D1 expression level (all

0.01).

Conclusion:

KAI exerted an anti-proliferative function by inhibiting IL-6/STAT3 signaling pathway followed by the induction of G

phase arrest in gastric cancer cells.

关键词

Keywords

Kang-Ai Injectiongastric cancerG1 arrestinterleukin-6signal transducer and activator of transcription 3Chinese herbal medicine

references

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin 2018;68:394-424.

Cervantes A, Roda D, Tarazona N, Roselló S, Pérez-Fidalgo JA. Current questions for the treatment of advanced gastric cancer. Cancer Treat Rev 2013;39:60-67.

He YH, Duan SM. Progress in using combination of Chinese drug with chemotherapy to treat cancer. J Tradit Chin Med(Chin) 2004;24:153-157.

Zhang JL. Clinical observation of combined Kangai Injection with TP in the treatment of advanced non-small cell lung cancer. J Modern Oncol (Chin) 2010;18:1132-1134.

Zheng F, Zhao Y, Li X, Tang Q, Wu J, Wu W, et al. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA Decoction and erlotinib. J Ethnopharm 2019;239:111928.

Zhang L, Xiong JP. Kangai Injection combined with chemotherapy in advanced gastric cancer. Cancer Res Prev Treat (Chin) 2009;36:328-330.

Han XQ, Han SQ. Inhibition effect of Kangai Injection on gastric cancer cell SGC-7901. J Basic Clin Oncol 2015;28:3-5.

Wang WR. Response of Kang-ai Injection in palliative treatment for advanced primary hepatocellular carcinoma. China Cancer(Chin) 2012;21:874-876.

Xu L, Zhang Y, Liu J, Qu JL, Hu XJ, Zhang F, et al. TRAIL-activated EGFR by Cbl-b-regulated EGFR redistribution in lipid rafts antagonises TRAIL-induced apoptosis in gastric cancer cells. Eur J Cancer 2012;48:3288-3299.

Ma HD, Deng YR, Tian Z, Lian ZX. Traditional Chinese medicine and immune regulation. Clin Rev Allergy Immunol 2013;44:229-241.

Zheng ZP, Xing SY, Yang WB, Shao Q, Huang LB, Lu HF, et al.Clinical study of kang'ai Injection combined with chemotherapy in the treatment of advanced lung cancer. Acta Acad Med Zunyi(Chin) 2012;35:209-212.

Lu Q, Li CL. Therapeutic efficacy and safety of Kang-ai Injection combined with platinum-based doublet chemotherapy in advanced NSCLC: a meta-analysis. Life Sci 2018;210:9-19.

Lin J, Huang SM, Zhu J, Chen SM, Chen WX, Wu GG, et al.Kang'ai Injection and palliative treatment of hepatocellular carcinoma and survival analysis in patients with advanced hepatocellular carcinoma. Chin Arch Tradit Chin Med (Chin)2018;36:1278-1280.

Cho WCS, Kwok Nam L. In vitro and in vivo immunomodulating and immunorestorative effects of Astragalus membranaceus. J Ethnopharm 2007;113:132-141.

He LX, Ren JW, Liu R, Chen QH, Zhao J, Wu X, et al. Ginseng(Panax ginseng Meyer) oligopeptides regulate innate and adaptive immune responses in mice via increased macrophage phagocytosis capacity, NK cell activity and Th cells secretion.Food Funct 2017;8:3523-3532.

Zheng K, Li C, Shan X, Liu H, Fan W, Wang Z. A study on isolation of chemical constituents from Sophora flavescens Ait.and their anti-glioma effects. Afr J Tradit Complement Altern Med 2014;11:156-160.

Tokunaga E, Oki EA, Sadanaga N, Morita M, Kakeji Y,Maehara Y. Deregulation of the Akt pathway in human cancer.Curr Cancer Drug Targ 2008;8:27-36.

Xavier DS, Filippos K, Sylvain M, Gerardo F. ERKs in cancer:friends or foes? Cancer Res 2014; 74:412-419.

Avalle L, Camporeale A, Camperi A, Poli V. STAT3 in cancer: a double edged sword. Cytokine 2017;98:42-50.

Li L, Wang SM, Zheng F, Wu WY, Hann SS. Chinese herbal medicine Fuzheng Kang-Ai Decoction sensitized the effect of gefitinib on inhibition of human lung cancer cells through inactivating PI3-K/Akt-mediated suppressing MUC1 expression.J Ethnopharm 2016;194:918-929.

Li L, Wang S, Yang X, Long S, Xiao S, Wu W, et al. Traditional Chinese medicine, Fuzheng Kang-Ai Decoction, inhibits metastasis of lung cancer cells through the STAT3/MMP9 pathway. Molecul Med Rep 2017;16:2461-2468.

Hill DG, Yu L, Gao H, Balic JJ, West A, Oshima H, et al.Hyperactive gp130/STAT3-driven gastric tumourigenesis promotes submucosal tertiary lymphoid structure development.Intern J Cancer 2018;143:167-178.

Lee SB, Shin JS, Han HS, Lee HH, Park JC, Lee KT, et al.Kaempferol 7-O-β-D-glucoside isolated from the leaves of Cudrania tricuspidata inhibits LPS-induced expression of pro-inflammatory mediators through inactivation of NF-κB, AP-1,and JAK-STAT in RAW 264.7 macrophages. Chem Biol Interact 2018;284:101-111.

Zhu M, Zhang W, Ma J, Dai Y, Zhang Q, Liu Q, et al. MicroRNA-139-5p regulates chronic inflammation by suppressing nuclear factor-kappaB activity to inhibit cell proliferation and invasion in colorectal cancer. Exp Ther Med 2019;18:4049-4057.

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Advances in Phytochemistry and Modern Pharmacology of Saposhnikovia Divaricata (Turcz.) Schischk

Efficacy of Chinese Herbal Medicines on Pregnancy Outcomes in Patients with Endometriosis in Long-Term Management: A Multicenter Retrospective Cohort Study

Chinese Medicine as Supporting Therapy for Psoriasis:Past, Present, and Future

Flavonoid-Rich Extract of Oldenlandia diffusa (Willd.) Roxb. Inhibits Gastric Cancer by Activation of Caspase-Dependent Mitochondrial Apoptosis

Sijunzi Decoction Inhibits Stemness by Suppressing β-Catenin Transcriptional Activity in Gastric Cancer Cells

Related Author

No data

Related Institution

College of Chinese Medicinal Materials, Jilin Agricultural University

Information Center, Jilin Agricultural University

College of Resources and Environment, Jilin Agricultural University

Department of Obstetrics and Gynecology, Beijing Friendship Hospital, Capital Medical University

Department of Obstetrics and Gynecology, Beijing Hospital

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰